news
Scmp World
2026-10-07
ArriVent shares tumble following failed China-licensed cancer drug trial
Shares of the US-based ArriVent BioPharma fell by 47% after a phase 3 trial for a cancer treatment licensed from a Chinese firm failed to meet its primary goals.